FDA Extends Casgevy’s Reach to Children as Young as Two, Reshaping the Sickle Cell Treatment Landscape 3 months ago AnaIn Breaking NewsFDA ApprovalsInnovationPharma Industry Updates
Orca Bio’s Tregzi Wins FDA Approval as First Regulatory T-Cell Therapy to Curb Chronic Graft-Versus-Host Disease 3 months ago AnaIn BreakthroughsFDA ApprovalsFeatured AnalysisResearch Updates
Epcoritamab Combination Hits Progression-Free Survival Mark in Phase 3 Lymphoma Trial, Genmab and AbbVie Report 3 months ago AnaIn BreakthroughsClinical TrialsPartnershipsResearch Updates
Biotech M&A Surpasses $106 Billion in 2026 as Big Pharma Races to Replenish Pipelines Before Patent Cliffs 3 months ago AnaIn DealsFunding RoundsInvestmentsPartnerships
Gilead’s Bictegravir/Lenacapavir Combination Wins FDA Priority Review, PDUFA Date Set for August 2026 3 months ago AnaIn FDA ApprovalsResearch UpdatesTop Stories
Definium’s DT120 Delivers Rapid, Durable Antidepressant Effect in Phase 3 EMERGE Trial — LSD Analogue Posts Landmark MDD Results 3 months ago AnaIn Breaking NewsClinical TrialsFeatured AnalysisResearch Updates
Australia’s TGA Grants Conditional Approval to Iovance’s Lifileucel — A First for T Cell Therapy in Solid Tumour Oncology 3 months ago AnaIn BreakthroughsClinical TrialsFeatured AnalysisInnovation
FDA Approves AstraZeneca’s Truqap Combination as First Targeted Therapy for PTEN-Deficient Metastatic Prostate Cancer 3 months ago AnaIn Breaking NewsFDA ApprovalsResearch Updates
Bemdaneprocel Phase I Data Show Sustained Motor Benefits at 36 Months in Parkinson’s Disease, Advancing Case for Cell Replacement 3 months ago AnaIn Biopharma HighlightsClinical Trials
NewLimit Raises $435 Million on Evidence of Age Reversal in Human Liver Cells, Plans First Clinical Trial 3 months ago AnaIn DealsFunding RoundsVenture Capital
FDA Approves First Oral Carbapenem for Complicated Urinary Tract Infections, Ending Decades of IV Dependency 3 months ago AnaIn FDA ApprovalsResearch Updates
Neurona Therapeutics Plans Phase 3 EPIC Trial After Rezanecel Shows Durable Seizure Reduction in 31-Patient Phase 1/2 Dataset 3 months ago AnaIn Biopharma HighlightsClinical Trials
Eli Lilly’s $7.8 Billion Centessa Deal Extends Neuroscience Ambitions into Orexin Signalling and Excessive Daytime Sleepiness 3 months ago AnaIn PartnershipsResearch Updates
FDA Clears First PROTAC Drug in History: Vepdegestrant Resets the Bar for ESR1-Mutant Breast Cancer Treatment 3 months ago AnaIn Breaking NewsClinical TrialsFDA Approvals
FDA Approves Xocova as First Oral Drug for COVID-19 Post-Exposure Prophylaxis 3 months ago AnaIn Biopharma HighlightsFDA ApprovalsResearch Updates
